Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Vicore Pharma Holding AB ( (SE:VICO) ).
Vicore Pharma Holding AB announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Global Healthcare Conference. These events, featuring CEO Ahmed Mousa and VP Megan Richards, will provide opportunities for the company to engage with investors and stakeholders, potentially enhancing its visibility and positioning within the healthcare industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, specifically angiotensin II type 2 receptor agonists (ATRAGs), for respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid (C21), is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
Average Trading Volume: 514,554
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.57B
See more data about VICO stock on TipRanks’ Stock Analysis page.